Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062073 · ClinicalTrials.gov registry record · Phase 1
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
A Phase 1 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 238
- Enrollment target
NCT02062073: Completed Phase 1 study, sponsored by Dr. Reddy's Laboratories Limited.
NCT02062073 is a Phase 1 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 238 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (297% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062073, a Phase 1 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 238 participants
- Enrollment target
Study Summary
Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.
Primary Outcome
Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation
Interventions
- DRUG Abametapir Lotion 0.74% w/w
- OTHER 0.1% sodium lauryl sulfate
- OTHER saline 0.9%
- OTHER Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT02062073 record still lists
NCT02062073 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (297% higher).
The record links to 0 conditions, and to 4 interventions - of which Abametapir Lotion 0.74% w/w is the first listed.
NCT02062073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02062073 about?
NCT02062073 is a clinical study titled "Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion". Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.
What is the current status of trial NCT02062073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 238 participants. The study started on 2014-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02062073?
The interventions under investigation include: Abametapir Lotion 0.74% w/w (DRUG), 0.1% sodium lauryl sulfate (OTHER), saline 0.9% (OTHER), Vehicle Lotion (OTHER).
Who is sponsoring clinical trial NCT02062073?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02062073's enrollment target sits among peer trials
238 212th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia